Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.42 |
| ▸ | MMP1 | P03956 | 4/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7202610 | 0.90 | MMP13 (0.42) | PKMADAM17MMP1MMP13MMP9 | |
| SCHEMBL7200927 | 0.90 | MMP13 (0.46) | ADAM17MMP1MMP13POLBTACR1 | |
| SCHEMBL7199718 | 0.88 | CARM1 (0.44) | PKMADAM17MMP1MMP13TACR1 | |
| SCHEMBL7200999 | 0.88 | MMP1 (0.46) | ADAM17MMP1MMP13TACR1 | |
| SCHEMBL7200956 | 0.88 | MMP2 (0.46) | ADAM17MMP1MMP13MMP9 | |
| SCHEMBL7202693 | 0.87 | FPR2 (0.44) | PKMADAM17MMP1MMP13MMP9 | |
| SCHEMBL7201226 | 0.86 | MMP13 (0.54) | PKMMMP1MMP13MMP9 | |
| SCHEMBL7208005 | 0.85 | MMP13 (0.42) | ADAM17MMP1MMP13MMP9ALDH1A1 | |
| SCHEMBL7204170 | 0.83 | HTR2C (0.48) | PKMADAM17MMP1MMP13MMP9 | |
| SCHEMBL7201688 | 0.83 | MMP13 (0.43) | ADAM17MMP1MMP13ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | PKM 3536/4885ADAM17 162/4885MMP1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.